Joint sensitivity spray cuts the risk of Covid-19 in the sudden trial

The trial, led by Professor Robert Plus, Director of the Fifth Internal Medicine Department at the Sarland University Medical Center and Professor of Internal Medicine at Sarland University, divided 450 participants into two groups. The treatment group of 227 people used nasal eternity spray three times a day during a 56 -day period. During that same period, 223 participants in the control group used a delusive drug spray three times a day. Robert Palz summarized the main result as follows: “During the monitoring period, 2.2 % of the eternal group participants have SARS-COV-2; in the imaginary drug group, 6.7 %-three times a lot. All infections were confirmed by the PCR test.

In addition to showing a noticeable decrease in Coronavin virus infections, the eteerine group also offered less than the sracing-2 infection of symptoms, a total number of confirmed respiratory infections, unexpectedly, decreased infections in the nasal viruses, and another major cause of respiratory disease. In the treatment group, 1.8 % developed a rhinoplasty infection, compared to 6.3 % in the imaginary drug group-a similar percentage of that seen for SARS-COV-2.

The eternal spray of the nose was available for decades as a treatment that does not depict straw fever. Previous laboratory studies on eternity have already suggested anti-viral effects against SARS-COV-2 and other respiratory viruses. Professor Plus says: “This clinical experience is the first to show a preventive effect in a real environment,” says Professor Plus.

For Robert Bilas, the results indicate practical applications: “The eternal spray of the nose can provide an additional accession that can be easily accessible to complete the current preventive measures, especially for weak groups, during periods of high infection rates, or before traveling.” But Professor Pal also stressed the importance of more research: “Our results arise the need for larger and multi -centers experiments to continue to explore the use of eternal nasal sprays as a preventive treatment upon request, and study its potential effectiveness against other respiratory pathogens.”

Besides Professor Bals, the random and double -blind study included “The Institute of Clinical Pharmacy (Professor Thorstan Leer, Dr. Dominic Cellser), the Institute of Viruses (Professor Segron Smoula), and a Sarbrokin pharmacy company, which was manufactured in the field of study. The Helmholtz Institute for Pharmaceutical Research, Sarland (Al -Warkan), has contributed through research groups from Professor Smola and Professor Pal. The project works as an excellent example of a successful cooperation between academic research, industry partners and public health initiatives in the Sarland region.

(Tagstotranslate) Allergy; Diseases and conditions; Infectious diseases; Today & amp;#039; health care ; Pharmaceuticals Covid and SARS. Eye care for personal medicine